Our initial solution is focused on the Type II Diabetes (T2D) pandemic. Our pharmacogenomic knowledge base captures clinical evidence for how genetic variations in patients affect their response to existing and emerging T2D drugs.
This knowledge is the foundation for the modeling, analytics and visualization capabilities that reduce the time and expense traditionally associated with delivering safe, efficacious treatments to T2D patients.
We offer advanced analytics powered by semantically linked pharmacogenomic and clinical data for innovative drug development and personalized therapy. This approach combined with carefully curated clinical knowledge for each therapeutic segment, leads our customers to better-informed clinical decisions.